Indian pharmaceuticals industry is growing at the CAGR of 13.6%.
Improvement in average disposable income.
Custom duty on drug intermeduates and bulk drug cuts to 7.7% from 12.8%,.formul
Indian pharma company has major number of USFDA approval
Indian pharma company has strong genric fundamentals.
Cut in excise duty to 8%, cut in custom duty to 5% on selected drugs and 12
IN 2008, US$ 20 billion of the drugs will be off patent.
1Sun pharmaceutical get the USFDA to market its generic version of Novartis Trileptal Oxcarbuzepine Tabl2Sun pharmaceutical receipt of a covenant Not to Sue from Wyeth over Sunpharma's Abbreviated New Dr 3Sun pharma recevied USFDA approval to market generic Protonix and also get a 180 days marketing excl4company get the USFDA approval for generic Razadyne,galantamine tablets. These generic have annual5company get the USFDA approval for generic Sinement CR Tablets.These generic have annual sale of U6company is growing at the rate of 18-20%.
8Depreciating INR against US dollars can fuel up the ,MORE REALIZATION AS
9HUGE RESERVES , NO DEBT TAKEN , SO NO INTEREST PAYMENT
Drugs approved by USFDA are cerebyx, generic ethyol, Metaprolol Tartrate, T